Jim Simons Aeterna Zentaris Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.17 - $0.37 $28,492 - $62,012	-167,600 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.33 - $0.42 $47,322 - $60,228	-143,400 Reduced 46.11%	167,600 $62,000
Q4 2021 Feb 11, 2022	SELL	$0.36 - $0.77 $10,944 - $23,408	-30,400 Reduced 8.9%	311,000 $110,000
Q3 2021 Nov 12, 2021	BUY	$0.59 - $0.88 $135,936 - $202,752	230,400 Added 207.57%	341,400 $256,000
Q2 2021 Aug 13, 2021	BUY	$0.83 - $1.14 $92,130 - $126,539	111,000 New	111,000 $97,000
Q3 2020 Nov 13, 2020	SELL	$0.34 - $0.55 $6,143 - $9,937	-18,069 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$0.42 - $1.44 $13,564 - $46,507	-32,297 Reduced 64.12%	18,069 $9,000
Q4 2019 Feb 13, 2020	SELL	$0.77 - $1.08 $21,087 - $29,577	-27,387 Reduced 35.22%	50,366 $46,000
Q3 2019 Nov 13, 2019	SELL	$1.0 - $2.97 $15,516 - $46,082	-15,516 Reduced 16.64%	77,753 $80,000
Q2 2019 Aug 12, 2019	SELL	$2.04 - $5.43 $34,290 - $91,272	-16,809 Reduced 15.27%	93,269 $275,000
Q1 2019 May 14, 2019	BUY	$3.03 - $4.65 $233,309 - $358,050	77,000 Added 232.78%	110,078 $512,000
Q4 2018 Feb 13, 2019	BUY	$1.3 - $3.87 $43,001 - $128,011	33,078 New	33,078 $97,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.